Bio Path Holdings

Bio Path Holdings ROA

Delisted·Sep 10, 2026

The Return on Assets (ROA) of Bio Path Holdings (BPTH) as of Oct 21, 2026 is -254.80 %. In the previous year, Return on Assets (ROA) was -499.32 % — a change of -48.97% (higher).

ROA

-254.80 %

YoY

-48.97%

Last updated:

In 2024, Bio Path Holdings's return on assets (ROA) was -254.80 %, a -48.97% increase from the -499.32 % ROA in the previous year.

The Bio Path Holdings ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2017
-79.28 USD
Jan 1, 2018
-367.58 USD
Jan 1, 2019
-37.53 USD
Jan 1, 2020
-65.89 USD
Jan 1, 2021
-39.28 USD
Jan 1, 2022
-86.63 USD
Jan 1, 2023
-499.32 USD
Jan 1, 2024
-254.80 USD
The Bio Path Holdings ROA history
YEARROAYoY
-254.80 %-48.97%
-499.32 %+476.41%
-86.63 %+120.51%
-39.28 %-40.38%
-65.89 %+75.56%
-37.53 %-89.79%
-367.58 %+363.62%
-79.28 %+43.25%
-55.35 %+8.89%
-50.83 %+74.06%
-29.20 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Bio Path Holdings Stock analysis

What does Bio Path Holdings do? Bio-Path Holdings, Inc. develops therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) using its DNAbilize technology platform. The company's drug delivery system, DNAbilize, utilizes P-ethoxy, a DNA backbone modification that protects antisense drugs from enzymatic destruction in the body. This platform enables systemic distribution of antisense drug substances to target over-expressed proteins in blood diseases and solid organs. Bio-Path has three antisense drug candidates in development targeting over five different cancer disease indications. The company's primary revenue stream comes from the development and commercialization of its antisense drug candidates. These therapies are designed to treat specific blood cancers and solid organ diseases where proteins are over-expressed. Bio-Path's technology allows for targeted protein inhibition without systemic toxicity, making it suitable for treating multiple cancer indications. The company focuses on developing therapies for AML and CML, which are serious blood disorders requiring specialized treatment approaches. Bio-Path Holdings, Inc. is a biotechnology company headquartered in Bellaire, Texas, with 10 full-time employees. It utilizes its DNAbilize platform to create antisense drug candidates that target over-expressed proteins in various diseases. The company's technology enables systemic delivery of antisense therapies across the body, allowing for reduction or elimination of disease-causing proteins. This approach is intended to provide targeted treatment for multiple cancer indications including AML and CML. Bio Path Holdings is one of the most popular companies on Eulerpool.

ROA Details

Understanding Bio Path Holdings's Return on Assets (ROA)

Bio Path Holdings's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Bio Path Holdings's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Bio Path Holdings's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Bio Path Holdings’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Bio Path Holdings stock

Return on Assets (ROA) of Bio Path Holdings is -254.80 % in 2024.

Return on Assets (ROA) of Bio Path Holdings changed from -499.32 % to -254.80 %, representing a -48.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Bio Path Holdings since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Bio Path Holdings with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Bio Path Holdings

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Bio Path Holdings